Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the <scp>OPTIMISMM</scp> Trial — Paul G. Richardson (2025) | RDL Network
Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the <scp>OPTIMISMM</scp> Trial
Article 2025 en
Authors
PR
Paul G. Richardson
MB
Meral Beksaç
AO
Albert Oriol
Abstract
1 min read
Findings showed a nonsignificant trend towards improved OS with PVd versus Vd. PFS2 favored PVd, supporting its use in RRMM.
Fredrik Schjesvold, Meletios A Dimopoulos, Meral Beksaç, Albert Oriol, Jindriska Lindsay, Anna Marina Liberati, Mónica Galli, Paweł Robak, Katja Weisel, Alessandra Larocca, Münci Yağcı, Filiz Vural, Larry Anderson, Abraham S. Kanate, Eva Casal Mendez, Ruiyun Jiang, Shankar Srinivasan, Lara Grote, Tsvetan Biyukov, Paul G. Richardson
Meletios A Dimopoulos, Katja Weisel, Philippe Moreau, Larry Anderson, Darrell White, Jesús F. San Miguel, Pieter Sonneveld, Monika Engelhardt, Matthew Jenner, Alessandro Corso, J. Dürig, Michel Pavic, Morten Salomo, Xiaoyong Yu, Tuong Vi Nguyen, Amine Bensmaine, Teresa Peluso, Mounir Zaki, Paul G. Richardson
Albert Oriol Rocafiguera, Meletios A Dimopoulos, Fredrik Schjesvold, Meral Beksaç, Münci Yağcı, Alessandra Larocca, Shien Guo, Yutian Mu, Kevin Hong, Sujith Dhanasiri, Paul G. Richardson, Katja Weisel
Albert Oriol, Meletios A Dimopoulos, Fredrik Schjesvold, M. Beksac, Münci Yağcı, Alessandra Larocca, S. Guo, Y. Mu, Kevin Hong, Sujith Dhanasiri, PG Richardson, Katja Weisel
Robert Z. Orlowski, Philippe Moreau, Rubén Niesvizky, Heinz Ludwig, Albert Oriol, Wee Joo Chng, Hartmut Goldschmidt, Zhao Yang, Amy Kimball, Meletios A Dimopoulos
Discussion(0)
No comments yet. Be the first to comment.